Event

Nick H. Kim

MD
UC San Diego Health;Univ of California San Diego;University of California San Diego;University of California San Diego Medical Center;University of California, San Diego

Lana Melendres-Groves

MD
Internal medicine;University of New Mexico

Erwan Muros-Le Rouzic

MPH
Actelion Pharmaceuticals Ltd.

Mona Selej

MD, MSc
Actelion Pharmaceuticals US Inc;Actelion Pharmaceuticals US, Inc

Kelly Chin

MD
Univ of Texas Southwestern Medical Center;University of Texas Southwestern;University of Texas, Southwestern Medical Center;UT Southwestern;UT Southwestern Medical Center

Vallerie V. McLaughlin

MD
Director of Pulmonary Hypertension Program, University of Michigan;University of Michigan;University of Michigan Medical Center

Richard N. Channick

MD
Mass General Harvard;Massachusetts General Hospital

Patient Characteristics and Treatment Patterns in the Largest Real-World Cohort of Pulmonary Arterial Hypertension Patients Newly Treated with Macitentan: OPsumit® USers (OPUS) Registry